Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-46

If my memory serves me correctly, ADVENT is the one that Jennifer Chow seemed most excited about.

I don't know if you're thinking what I am thinking, but the simplicity and safety of the CORE-NK cell technology would be attractive to potential collaborators. Here we are, trialing CORE-NK with the front-line drugs for AML.

It's the non-engineered enhancement of NK cells to do what they do naturally and, that is, kill tumour cells. It's free of the associated toxicity issues that T-cells present and the injected NK cells are enhanced for persistence and activity. Seems like the perfect combo-therapy potential for other modalities, such as monoclonal antibodies or checkpoint inhibitors, to enhance the overall anti-tumor effect.

What you have stated about Merck being on the hunt with Keytruda coming up for patent expiry is very relevant. Having CORE-NK under investigation by MD Anderson in combo with two standard-of-care drug lines for AML seems most strategic. A potentially quick route to commercialisation and/or licensing agreements.